<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04225078</url>
  </required_header>
  <id_info>
    <org_study_id>CR108643</org_study_id>
    <secondary_id>2019-003776-39</secondary_id>
    <secondary_id>R018553NAP1001</secondary_id>
    <nct_id>NCT04225078</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of Loperamide (JNJ-289679) on Electrocardiogram Intervals in Healthy Adult Participants</brief_title>
  <official_title>A Randomized, Double-blind, Placebo- and Positive-controlled, Single-dose, 4 Way Crossover Study to Evaluate the Effects of Loperamide (JNJ-289679) on Electrocardiogram Intervals in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of loperamide on QT/ QT interval corrected&#xD;
      for heart rate (QTc) intervals and electrocardiogram (ECG) morphology at therapeutic and&#xD;
      supratherapeutic exposures in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2020</start_date>
  <completion_date type="Anticipated">December 16, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 16, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in QT Interval Corrected for Heart Rate (QTc) Intervals for Loperamide</measure>
    <time_frame>Baseline up to 9 weeks</time_frame>
    <description>Change from baseline in QTc intervals for loperamide at therapeutic and supratherapeutic doses will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Change from Baseline in T-wave Morphology</measure>
    <time_frame>Up to 9 weeks</time_frame>
    <description>The percentage of participants in each treatment having T-wave morphology changes from baseline that represent the appearance or worsening of the morphological abnormality will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Occurrence of Abnormal U-wave Morphology</measure>
    <time_frame>Up to 9 weeks</time_frame>
    <description>The percentage of participants with the occurrence of abnormal U-waves morphology that represent the appearance or worsening of the morphological abnormality will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Loperamide and its M1 Metabolite</measure>
    <time_frame>Up to 9 weeks</time_frame>
    <description>Cmax is defined as the maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Observed Plasma Concentration (Tmax) of Loperamide and its M1 Metabolite</measure>
    <time_frame>Up to 9 weeks</time_frame>
    <description>Tmax is defined as the time to reach the maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from the Time of Dosing to the Last Measurable Plasma Concentration AUC (0-last) of Loperamide and its M1 Metabolite</measure>
    <time_frame>Up to 9 weeks</time_frame>
    <description>AUC (0-last) is defined as the area under the plasma concentration-time curve from the time of dosing to the last measurable plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC[0-inifinity]) of Loperamide and M1 Metabolite</measure>
    <time_frame>Up to 9 weeks</time_frame>
    <description>(AUC[0-inifinity]) is defined as the area under the plasma concentration-time curve from time zero to infinity, calculated as AUClast+Clast/lambda (z), where Clast is the last observed measurable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Elimination Rate Constant Lambda (z) of Loperamide and its M1 Metabolite</measure>
    <time_frame>Up to 9 weeks</time_frame>
    <description>Lambda (z) is defined as the apparent terminal elimination rate constant, estimated by linear regression using the terminal log-linear phase of the log-transformed concentration versus time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Elimination Half-Life Associated with the Terminal Slope (t1/2) of Loperamide and M1 Metabolite</measure>
    <time_frame>Up to 9 weeks</time_frame>
    <description>t1/2 is defined as the apparent elimination half-life associated with the terminal slope lambda (z) of the semilogarithmic drug concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite to parent ratio (M/P) for (AUC[0-inifinity]) of Loperamide and M1 Metabolite</measure>
    <time_frame>Up to 9 weeks</time_frame>
    <description>M/p ratio is defined as metabolite to parent ratio (M/P) for (AUC[0-inifinity]) corrected for molecular weight using the following molecular weights: loperamide 477.045 gram per mol (g/mol), M1 463.018 g/mol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Systemic Plasma Concentrations of Loperamide and QT/QTc Changes</measure>
    <time_frame>Up to 9 weeks</time_frame>
    <description>The relationship between systemic plasma concentrations of loperamide and change in QT/QTc will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AE) as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to 9 Weeks</time_frame>
    <description>An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence 1: Treatment ADBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive treatment A (Loperamide therapeutic dose) on Day 1 on treatment period 1, followed by Treatment D (Moxifloxacin) on Day 1 of treatment period 2 followed by Treatment B (Loperamide supratherapeutic dose) on Day 1 of treatment period 3 followed by Treatment C (placebo) on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 2: Treatment BACD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment B on Day 1 of treatment period 1 followed by Treatment A on Day 1 of treatment period 2 then Treatment C on Day 1 of treatment period 3 and then Treatment D on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 3: Treatment CBDA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment C on Day 1 of treatment period 1 followed by Treatment B on Day 1 of treatment period 2 then Treatment D on Day 1 of treatment period 3 and then Treatment A on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 1: Treatment DCAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment D on Day 1 of treatment period 1 followed by Treatment C on Day 1 of treatment period 2 then Treatment A on Day 1 of treatment period 3 and then Treatment B on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loperamide</intervention_name>
    <description>Loperamide will be administered as a single oral dose at the expected therapeutic or supratherapeutic doses respectively.</description>
    <arm_group_label>Treatment Sequence 1: Treatment ADBC</arm_group_label>
    <arm_group_label>Treatment Sequence 1: Treatment DCAB</arm_group_label>
    <arm_group_label>Treatment Sequence 2: Treatment BACD</arm_group_label>
    <arm_group_label>Treatment Sequence 3: Treatment CBDA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching loperamide placebo capsules will be administered orally.</description>
    <arm_group_label>Treatment Sequence 1: Treatment ADBC</arm_group_label>
    <arm_group_label>Treatment Sequence 1: Treatment DCAB</arm_group_label>
    <arm_group_label>Treatment Sequence 2: Treatment BACD</arm_group_label>
    <arm_group_label>Treatment Sequence 3: Treatment CBDA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Moxifloxacin tablets will be administered orally.</description>
    <arm_group_label>Treatment Sequence 1: Treatment ADBC</arm_group_label>
    <arm_group_label>Treatment Sequence 1: Treatment DCAB</arm_group_label>
    <arm_group_label>Treatment Sequence 2: Treatment BACD</arm_group_label>
    <arm_group_label>Treatment Sequence 3: Treatment CBDA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All female participants, except if postmenopausal, must have a negative serum&#xD;
             beta-human chorionic gonadotropin (beta hCG) pregnancy test at screening and a&#xD;
             negative urine pregnancy test on Day 1 of each treatment period&#xD;
&#xD;
          -  A female participant must agree not to donate eggs (ova, oocytes) for the purposes of&#xD;
             assisted reproduction during the study and for at least 1 month after the last study&#xD;
             drug administration&#xD;
&#xD;
          -  A male participant, who is sexually active with a woman of childbearing potential and&#xD;
             has not had a vasectomy, must agree to use an adequate contraception method as deemed&#xD;
             appropriate by the investigator (example, vasectomy, double-barrier, partner using&#xD;
             effective contraception) and to not donate sperm during the study and for 3 months&#xD;
             after receiving the last dose of study drug&#xD;
&#xD;
          -  Must have a body mass index (body mass index [BMI]; weight kilogram per meter per&#xD;
             height per square per meter square [kg/height^2 m^2]) between 18.0 and 30.0 kg/m^2&#xD;
             (inclusive) with a body weight not lower than 50 kilogram (kg)&#xD;
&#xD;
          -  Must have a blood pressure (after the participant is supine for 5 minutes) between 90&#xD;
             and 140 millimeters of Mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg&#xD;
             diastolic. Heart rate between 45 and 100 beats per minute (bpm), inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of or current renal insufficiency (estimated glomerular filtration rate [eGFR]&#xD;
             less than (&lt;) 90 milliliter per minute per meter square (mL/min/1.73m^2) based on the&#xD;
             Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula at screening only)&#xD;
&#xD;
          -  Clinically significant abnormal values for hematology, serum chemistry (including&#xD;
             thyroid-stimulating hormone [TSH] at screening only) or urinalysis at screening or at&#xD;
             admission to the study site, as deemed appropriate by the investigator. It is expected&#xD;
             that laboratory values will generally be within the normal range for the laboratory,&#xD;
             though minor deviations, which are not considered to be of clinical significance to&#xD;
             the investigator, are acceptable&#xD;
&#xD;
          -  Clinically significant abnormal physical examination, vital signs, or 12-lead&#xD;
             electrocardiogram (ECG) at screening or at admission to the study site as deemed&#xD;
             appropriate by the investigator&#xD;
&#xD;
          -  Received a known inhibitor of Cytochrome (CY) P3A4, CYP3A4, CYP2C8, or P-glycoprotein&#xD;
             (P-gp) activity within 14 days or a period less than 5 times the drugs' half-life;&#xD;
             whichever is longer, before the first dose of the study drug is scheduled&#xD;
&#xD;
          -  Received a known inducer of CYP3A4 or CYP2C8 activity within 28 days before the first&#xD;
             dose of the study drug is scheduled&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Pharmacology Unit</name>
      <address>
        <city>Merksem</city>
        <zip>2170</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108643</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Loperamide</mesh_term>
    <mesh_term>Antidiarrheals</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency.&#xD;
As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

